https://www.fiercebiotech.com/biotech/boehringer-ingelheim-digs-adcs-offering-nearly-1b-license-cancer-prospect-koreas-aimedbio
Boehringer digs in on ADCs with $991M AimedBio licensing accord
Oct 15, 2025 - After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well.
digs inboehringeradcsaimedbiolicensing